Email Updates

Search form

Place quotation marks around exact phrases (e.g. "new york"). Note: Trial names have a space before the number (e.g. HVTN 100).

You are here

Home

Trial Search

Trial Name Prevention Option Phase Start Date Sponsors Countries Population Candidate(s) Status
HVTN 124 HIV Vaccine I February 2018 DAIDS United States of America Women, Men gp120 (A,B,C,A/E)/GLA-SE, env (A,B,C,A/E)/gag (C)/GLA-SE Ongoing
HVTN 122 HIV Vaccine I January 2018 DAIDS United States of America Women, Men gp145 C.6980 Ongoing
HVTN 120 HIV Vaccine I/II March 2018 NIAID South Africa, United Republic of Tanzania, Zimbabwe, Zambia, United States of America Women, Men ALVAC/gp120/MF59, ALVAC/gp120/AS01(B) Ongoing
HVTN 119 HIV Vaccine I July 2017 DAIDS United States of America HIV negative DNA plasmid Ongoing
HVTN 115 HIV Vaccine I October 2017 DAIDS United States of America Women, Men CH505TF Ongoing
HPX2008/ HVTN 705 HIV Vaccine IIb November 2017 Janssen Vaccines & Prevention B.V. Malawi, Mozambique, South Africa, Zambia, Zimbabwe Women Ad26.Mos.HIV, gp140 Ongoing
HPX2003/HVTN118/IPCAVD012/ASCENT HIV Vaccine I/II March 2017 Janssen, HVTNNIAID, MHRP, BIDMC, Ragon United States of America Ad26.Mos.HIV, gp140 Ongoing
HVTN 117/HPX2004/IPCAVD011/TRAVERSE HIV Vaccine I/II June 2016 Janssen, HVTNNIAID, MHRP, BIDMC, Ragon United States of America, Rwanda Women, Men Ad26.Mos.HIV, gp140 Ongoing
Study of Safety and Immunogenicity of HIV Vaccines in Healthy Volunteers HIV Vaccine I October 2013 NIAID, PaxVax United States of America Women, Men Ad4 Ongoing
Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults HIV Vaccine I March 2016 Crucell Holland BV Clinical Trial United States of America Women, Men Ad26.Mos.HIV, gp140 Ongoing
Study of Immune Responses Induced by a HIV Vaccine (RV328) HIV Vaccine II July 2014 U.S. Army Medical Research and Materiel Command, NIH Thailand Women, Men AIDSVAX Ongoing
HVTN 112 HIV Vaccine I March 2016 NIAID United States of America Women, Men rVSV Ongoing
HVTN 110 HIV Vaccine I March 2015 United States of America Women, Men Ad4, AIDSVAX, gp120 Ongoing
HVTN 098 HIV Vaccine I August 2016 NIAID United States of America Women, Men IL-12, PENNVAX Ongoing
HVTN 107 HIV Vaccine I/II March 2017 NIAID South Africa, Mozambique, Zimbabwe Women, Men ALVAC, gp120 Ongoing
HVTN 108 HIV Vaccine I/II December 2016 United States of America, South Africa Women, Men DNA plasmid, gp120 Ongoing
HVTN 702 HIV Vaccine III, IIb October 2016 NIAID South Africa Women, Men ALVAC, gp120 Ongoing
HVTN 111 HIV Vaccine I May 2016 HIV Vaccine Trials Network, DAIDS, BMGF, GSK, IPPOX South Africa, United Republic of Tanzania, Zambia Women, Men gp120 Ongoing
HVTN 106 HIV Vaccine I January 2015 National Institute of Allergy and Infectious Diseases (NIAID), CHAVI, IPPOX, MHRP, HIV Vaccine Trials Network United States of America, Switzerland Women, Men DNA , MVA Ongoing
HVTN 100 HIV Vaccine I/II January 2015 National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network Bill and Melinda Gates Foundation, Medical Research Council Sanofi Pasteur, a Sanofi Company, Novartis Vaccines South Africa Women, Men ALVAC, gp120 Ongoing

Pages

CSVDoc